Contact: Dennis J. Curtin, Senior Vice President - Chief Financial Officer
Telephone: 1-800-544-4624, ext. 3320
Email: dcurtin@ezem.com

E-Z-EM, Inc. Announces Results for the Second Quarter 2003

Lake Success, New York; January 14, 2003 E-Z-EM, Inc., (AMEX: EZM) today announced results for 
the second fiscal quarter of 2003 ended November 30, 2002. The Company reported net earnings of 
$988,000, or $.10 per basic share and $.09 per diluted share, on net sales of $32,900,000. In 
the second quarter of fiscal 2002, the Company reported a net loss of $1,167,000, or ($.12) per 
basic and diluted share on net sales of $30,629,000. The Company attributed the improved results 
to increased sales of its core radiology imaging products for the CT market, and to the continued
performance of its AngioDynamics subsidiary in the Interventional Radiology sector. Results for 
the comparative prior year quarter included a restructuring charge of $1,532,000, or $.16 per 
basic share, associated with the December 2001 closure of the Company’s liquid contrast 
manufacturing facility in Japan.

For the first six months of fiscal 2003, the Company reported net earnings of $247,000, or 
$.02 per basic and diluted share, on net sales of $63,180,000. In the comparable period of the 
previous year, the Company reported a net loss of $1,279,000, or ($.13) per basic and diluted 
share, on net sales of $58,270,000.

Commenting on the announcement, Anthony A. Lombardo, E-Z-EM President and CEO stated, "Our 
strategic plan of investing in growing market segments is beginning to achieve its objectives, 
as evidenced by sales growth of our two radiology business segments. The Company's net sales for 
the quarter and year-to-date were up 7% and 8%, respectively, from the previous year, reflecting 
the growth in CT and Interventional Radiology - sectors that are fueling the overall radiology 
marketplace. Our core EZEM segment recorded 5% sales growth for both the quarter and year-to-date 
on strong sales of CT imaging products such as Readi-CAT® and our family of CT Smoothies, 
products that remain the first choice for abdominal imaging procedures. The Dysphagia product 
line also established itself as the leader for swallowing studies, and our Empower CT(TM) 
injector system continued to gain installed base and is now being utilized by major medical 
centers nationwide. Recently, the Company exhibited potential enhancements to its Virtual 
Colonoscopy product portfolio, with the work-in progress display of a prototype Computed Aided 
Diagnosis (CAD) application with Vital Images and R2 Technology. CAD technology is expected to 
play a major role in radiology diagnosis in the future, and though no formal agreement yet 
exists for the development of a Colon CAD solution, the application was recently demonstrated 
by the three companies at the 88th Annual Scientific Assembly of the Radiological Society of 
North America.

"We are also pleased by the continued strong performance of our AngioDynamics group, which 
recorded sales growth of 15% for the quarter and 19% for the year-to-date. Sales increased for 
products in the dialysis area, as represented by MoreFlow(TM) and DuraFlow(TM), and we continue 
to build strong brand identity in this segment. We have also experienced growth from our Micro 
Access product sets, and from our recently introduced ELVS(TM) endovascular laser system - a 
new product for the treatment of varicose veins that offers great potential for reducing 
procedure time and improving patient clinical outcomes. We expect this product will help to 
position AngioDynamics in this area.

"Operating expenses for the current six months increased 16% from the previous year, excluding 
the effect of the aforementioned Japanese restructuring charge. Operating expenses for the 
current period included $688,000 in costs related to the recapitalization, during the second 
quarter, of the Company's two classes of common stock into a single, newly created class of 
common stock. Contributing to these increased operating expenses are the investments we continue 
to make aimed at positioning the Company for further growth. We have expanded the AngioDynamics 
sales force and continue to make other investments in product development and in the sales and 
marketing infrastructure required to support new product releases. We continue to believe that 
these investments will have a positive impact on sales in succeeding quarters."

The Company’s cash, cash equivalents and short-term marketable securities at November 30, 2002 
were $16.7 million. Net book value was $8.22 per basic share at November 30, 2002. The Company’s 
balance sheet and financial position remain strong. 

About E-Z-EM, Inc.

E-Z-EM is the world’s largest manufacturer of contrast agents for gastrointestinal radiology. 
The Company has developed the only CT injector on the market that can help detect contrast 
extravasation, the EmpowerCT(TM) with patented EDA(TM) technology; it also offers a complete 
tool kit for the virtual colonoscopy practitioner. This product line consists of virtual 
colonoscopy hardware, software, nutritional prep kits and bowel cleaners, tagging agents and a 
carbon dioxide colon insufflation system. E-Z-EM’s wholly-owned subsidiary, AngioDynamics, 
manufactures a wide range of products, including angiographic, vascular access, thrombolytic, 
angioplasty, stents, as well as abdominal infection drainage products. AngioDynamics’ focus is 
on diagnostic and therapeutic products for interventional radiology and other areas of 
minimally invasive surgery. Enteric Products, Inc., another subsidiary, develops, manufactures 
and markets tests for detection of the ulcer- and cancer-causing bacterium Helicobacter pylori. 
For additional information, please contact Tom Johnson at 1-800-544-4624, ext. 317, (E-mail: 
tjohnson@ezem.com) or visit our corporate web site at www.ezem.com.

The statements made in this document contain certain forward-looking statements that involve a 
number of risks and uncertainties. Words such as "expects", "intends", "anticipates", "plans", 
"believes", "seeks", "estimates," or variations of such words and similar expressions, are 
intended to identify such forward-looking statements. Investors are cautioned that actual 
events or results may differ from the Company’s expectations. In addition to the matters 
described above, the ability of the Company to develop its products, future actions by the FDA 
or other regulatory agencies, results of pending or future clinical trials, overall economic 
conditions, general market conditions, foreign currency exchange rate fluctuations, the effects 
on pricing from Group Purchasing Organizations, competition, including alternative procedures 
which continue to replace traditional fluoroscopic procedures, as well as the risk factors 
listed from time to time in the SEC filings of E-Z-EM, Inc., including but not limited to its 
Form 10-Q for the quarter ended November 30, 2002, as well as its Annual Report on Form 10-K 
for the year ended June 1, 2002, may affect the actual results achieved by the Company. 

End